4.8 Article

Risk of variceal hemorrhage and pretransplant mortality in children with biliary atresia

期刊

HEPATOLOGY
卷 76, 期 3, 页码 712-726

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1002/hep.32451

关键词

-

资金

  1. NIDDK [DK 62445, DK 62497, DK 62470, DK 62481, DK 62456, DK 84536, DK 84575, DK 62500, DK 62466, DK 62453, DK103149, DK103135, DK103140]
  2. National Institutes of Health
  3. Clinical and Translational Sciences Award (NCATS CTSA) grants from University of Colorado [UL1 TR002535]
  4. UCSF Children's Hospital [UL1 TR001872]
  5. Children's Hospital of Pittsburgh of UPMC [UL1 TR001857]
  6. Seattle Children's Hospital [UL1 TR000423, UL1 RR025014, UL1TR002378]
  7. Children's Hospital of Philadelphia [UL1 TR001878]
  8. Children's Healthcare of Atlanta [UL1TR002378]
  9. Children's Hospital of Los Angeles [UL1TR00130]
  10. National Center for Advancing Translational Sciences

向作者/读者索取更多资源

The incidence of gastroesophageal variceal hemorrhage (VH) in biliary atresia (BA) patients is low and associated with features of portal hypertension and clinical parameters. The mortality rate of VH in this population is also relatively low. These findings should be considered in screening for varices and primary prophylaxis of VH.
Background and Aims The natural history of gastroesophageal variceal hemorrhage (VH) in biliary atresia (BA) is not well characterized. We analyzed risk factors, incidence, and outcomes of VH in a longitudinal multicenter study. Approach and Results Participants enrolled in either an incident (Prospective Database of Infants with Cholestasis [PROBE]) or prevalent (Biliary Atresia Study of Infants and Children [BASIC]) cohort of BA were included. Variceal hemorrhage (VH) was defined based on gastrointestinal bleeding in the presence of varices accompanied by endoscopic or nontransplant surgical intervention. Cumulative incidence of VH and transplant-free survival was compared based on features of portal hypertension (e.g., splenomegaly, thrombocytopenia) and clinical parameters at baseline in each cohort (PROBE: 1.5 to 4.5 months after hepatoportoenterostomy [HPE]; BASIC: at enrollment > 3 years of age). Analyses were conducted on 869 children with BA enrolled between June 2004 and December 2020 (521 in PROBE [262 (51%) with a functioning HPE] and 348 in BASIC). The overall incidence of first observed VH at 5 years was 9.4% (95% CI: 7.0-12.4) in PROBE and 8.0% (5.2-11.5) in BASIC. Features of portal hypertension, platelet count, total bilirubin, aspartate aminotransferase (AST), albumin, and AST-to-platelet ratio index at baseline were associated with an increased risk of subsequent VH in both cohorts. Transplant-free survival at 5 years was 45.1% (40.5-49.6) in PROBE and 79.2% (74.1-83.4) in BASIC. Two (2.5%) of 80 participants who had VH died, whereas 10 (12.5%) underwent transplant within 6 weeks of VH. Conclusions The low risk of VH and associated mortality in children with BA needs to be considered in decisions related to screening for varices and primary prophylaxis of VH.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Gastroenterology & Hepatology

Fat Soluble Vitamin Assessment and Supplementation in Cholestasis

Binita M. Kamath, Estella M. Alonso, James E. Heubi, Saul J. Karpen, Shikha S. Sundaram, Benjamin L. Shneider, Ronald J. Sokol

CLINICS IN LIVER DISEASE (2022)

Article Gastroenterology & Hepatology

Macronutrient and Micronutrient Intake in Adolescents With Non-alcoholic Fatty Liver Disease: The Association With Disease Severity

Ariel Porto, Zhaoxing Pan, Wenru Zhou, Ronald J. Sokol, Kelly Klaczkiewicz, Shikha S. Sundaram

Summary: This study aimed to evaluate the macronutrient and micronutrient intake in adolescents with NAFLD and determine nutritional predictors of disease severity. The results showed that NAFLD patients had similar intake of total calories, protein, fat, and carbohydrates as those without NASH, but NASH patients had higher sugar intake. The severity of the liver disease was correlated with total carbohydrate and added sugar intake.

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2022)

Article Critical Care Medicine

Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients

Matthew K. Wynia, Laurel E. Beaty, Tellen D. Bennett, Nichole E. Carlson, Christopher B. Davis, Bethany M. Kwan, David A. Mayer, Toan C. Ong, Seth Russell, Jeffrey D. Steele, Heather R. Stocker, Adane F. Wogu, Richard D. Zane, Ronald J. Sokol, Adit A. Ginde

Summary: This observational cohort study found that treatment with neutralizing monoclonal antibodies (mAbs) was associated with reduced hospitalization and deaths among COVID-19 outpatients. The benefits of mAb treatment persisted during the Delta variant phase.
Article Gastroenterology & Hepatology

Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease

Daniel H. Leung, Sridevi Devaraj, Nathan P. Goodrich, Xinpu Chen, Deepthi Rajapakshe, Wen Ye, Victor Andreev, Charles G. Minard, Danielle Guffey, Jean P. Molleston, Lee M. Bass, Saul J. Karpen, Binita M. Kamath, Kasper S. Wang, Shikha S. Sundaram, Philip Rosenthal, Patrick McKiernan, Kathleen M. Loomes, M. Kyle Jensen, Simon P. Horslen, Jorge A. Bezerra, John C. Magee, Robert M. Merion, Ronald J. Sokol, Benjamin L. Shneider

Summary: This study investigated biomarkers for hepatic fibrosis in pediatric cholestasis patients. The researchers found that endoglin, IL-8, and MMP-7 were positively correlated with liver stiffness in children with biliary atresia, while CTGF was negatively correlated in alpha-1 antitrypsin deficiency patients. These biomarkers may enhance the prediction of liver stiffness and facilitate early interventions.

HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Serum bile acids as a prognostic biomarker in biliary atresia following Kasai portoenterostomy

Sanjiv Harpavat, Kieran Hawthorne, Kenneth D. R. Setchell, Monica Narvaez Rivas, Lisa Henn, Charlotte A. Beil, Saul J. Karpen, Vicky L. Ng, Estella M. Alonso, Jorge A. Bezerra, Stephen L. Guthery, Simon Horslen, Kathy M. Loomes, Patrick McKiernan, John C. Magee, Robert M. Merion, Jean P. Molleston, Philip Rosenthal, Richard J. Thompson, Kasper S. Wang, Ronald J. Sokol, Benjamin L. Shneider

Summary: Serum bile acid levels may help predict outcomes in infants with normalized bilirubin levels after Kasai portoenterostomy.

HEPATOLOGY (2023)

Article Multidisciplinary Sciences

The autophagic protein p62 is a target of reactive aldehydes in human and murine cholestatic liver disease

Colin T. Shearn, Aimee L. Anderson, Michael W. Devereux, David J. Orlicky, Cole Michel, Dennis R. Petersen, Colin G. Miller, Sanjiv Harpavat, Edward E. Schmidt, Ronald J. Sokol

Summary: This study investigates the interactions between oxidative stress and autophagy in cholestasis using mouse and human liver tissue. The results show a dysregulation of oxidative stress and autophagy in the same periportal hepatocyte compartment, suggesting that increased expression of oxidatively-modified proteins and ineffective autophagic degradation may contribute to liver cell injury.

PLOS ONE (2022)

Article Gastroenterology & Hepatology

Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor

Ronald J. Sokol, Emmanuel M. Gonzales, Binita M. Kamath, Alastair Baker, Pamela Vig, Douglas B. Mogul, Will Garner, Bettina E. Hansen, Emmanuel Jacquemin, Richard J. Thompson

Summary: Improvement in pruritus by 48 weeks, and lower W48 bilirubin and serum bile acid levels were associated with fewer events in patients with Alagille syndrome (ALGS) treated with maralixibat (MRX).

HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Clinical spectrum and genetic causes of mitochondrial hepatopathy phenotype in children

James E. Squires, Alexander G. Miethke, C. Alexander Valencia, Kieran Hawthorne, Lisa Henn, Johan L. K. H. Van Hove, Robert Squires, Kevin Bove, Simon Horslen, Rohit Kohli, Jean P. Molleston, Rene Romero, Estella M. Alonso, Jorge A. Bezerra, Stephen L. Guthery, Evelyn Hsu, Saul J. Karpen, Kathleen M. Loomes, Vicky L. Ng, Philip Rosenthal, Krupa Mysore, Kasper S. Wang, Marisa W. Friederich, John C. Magee, Ronald J. Sokol

Summary: This study aims to enhance the understanding of pathogenesis and natural history of mitochondrial hepatopathies (MH), a range of liver-based conditions caused by alterations in mitochondrial DNA and nuclear DNA genes. The study found differences in clinical presentation, genetic etiology, and survival between acute liver failure (ALF) and chronic liver disease (Chronic) phenotypes of MH. In addition, a subset of patients could not be identified with a specific genetic or enzymatic diagnosis, highlighting the need for further research.

HEPATOLOGY COMMUNICATIONS (2023)

Article Gastroenterology & Hepatology

Stat3 role in the protective effect of FXR Agonist in parenteral nutrition-associated cholestasis

Swati Ghosh, Michael W. Devereaux, Aimee L. Anderson, Karim C. El Kasmi, Ronald J. Sokol

Summary: The study showed that FXR activation through IL-6-STAT3 signaling in a PNAC mouse model alleviated cholestatic liver injury and prevented cholestasis.

HEPATOLOGY COMMUNICATIONS (2023)

Article Gastroenterology & Hepatology

Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency

Antonia Felzen, Daan B. E. van Wessel, Emmanuel Gonzales, Richard J. Thompson, Irena Jankowska, Benjamin L. Shneider, Etienne Sokal, Tassos Grammatikopoulos, Agustina Kadaristiana, Emmanuel Jacquemin, Anne Spraul, Patryk Lipinski, Piotr Czubkowski, Nathalie Rock, Mohammad Shagrani, Dieter Broering, Emanuele Nicastro, Deirdre Kelly, Gabriella Nebbia, Henrik Arnell, Bjoern Fischler, Jan B. F. Hulscher, Daniele Serranti, Cigdem Arikan, Esra Polat, Dominique Debray, Florence Lacaille, Cristina Goncalves, Loreto Hierro, Gema Munoz Bartolo, Yael Mozer-Glassberg, Amer Azaz, Jernej Brecelj, Antal Dezsofi, Pier Luigi Calvo, Enke Grabhorn, Steffen Hartleif, Wendy J. van der Woerd, Binita M. Kamath, Jian-She Wang, Liting Li, Ozlem Durmaz, Nanda Kerkar, Marianne Horby Jorgensen, Ryan Fischer, Carolina Jimenez-Rivera, Seema Alam, Mara Cananzi, Noemie Laverdure, Cristina Targa Ferreira, Felipe Ordonez Guerrero, Heng Wang, Valerie Sency, Kyung Mo Kim, Huey-Ling Chen, Elisa de Carvalho, Alexandre Fabre, Jesus Quintero Bernabeu, Aglaia Zellos, Estella M. Alonso, Ronald J. Sokol, Frederick J. Suchy, Kathleen M. Loomes, Patrick J. McKiernan, Philip Rosenthal, Yumirle Turmelle, Simon Horslen, Kathleen Schwarz, Jorge A. Bezerra, Kasper Wang, Bettina E. Hansen, Henkjan J. Verkade

Summary: This study aimed to evaluate the relationship between genetic mutations related to BSEP deficiency and clinical features. The results showed that the combination of one relatively mild mutation and one severe mutation resulted in a clinical presentation similar to patients with two severe mutations, and they had a poor response to surgical interruption of the enterohepatic circulation.

JHEP REPORTS (2023)

Article Gastroenterology & Hepatology

Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis

Richard J. Thompson, Reha Artan, Ulrich Baumann, Pier Luigi Calvo, Piotr Czubkowski, Buket Dalgic, Lorenzo D'Antiga, Angelo Di Giorgio, Ozlem Durmaz, Emmanuel Gonzales, Tassos Grammatikopoulos, Girish Gupte, Winita Hardikar, Roderick H. J. Houwen, Binita M. Kamath, Saul J. Karpen, Florence Lacaille, Alain Lachaux, Elke Lainka, Kathleen M. Loomes, Cara L. Mack, Jan P. Mattsson, Patrick Mckiernan, Quanhong Ni, Hasan Ozen, Sanjay R. Rajwal, Bertrand Roquelaure, Eyal Shteyer, Etienne Sokal, Ronald J. Sokol, Nisreen Soufi, Ekkehard Sturm, Mary Elizabeth Tessier, Wendy L. van der Woerd, Henkjan J. Verkade, Jennifer M. Vittorio, Terese Wallefors, Natalie Warholic, Qifeng Yu, Patrick Horn, Lise Kjems

Summary: The ongoing PEDFIC 2 study evaluated the effectiveness of odevixibat in patients with progressive familial intrahepatic cholestasis. The study found that odevixibat can reduce serum bile acids and alleviate pruritus symptoms. This suggests that odevixibat may be a safe and effective treatment option for patients with progressive familial intrahepatic cholestasis.

JHEP REPORTS (2023)

Article Gastroenterology & Hepatology

Cytomegalovirus in biliary atresia is associated with increased pretransplant death, but not decreased native liver survival

Sarah Kemme, Jennifer D. Canniff, Amy G. Feldman, Krystle M. Garth, Shaobing Li, Zhaoxing Pan, Ronald J. Sokol, Adriana Weinberg, Cara L. Mack

Summary: This study aimed to investigate the relationship between cytomegalovirus (CMV) infection and the severity of disease and pretransplant outcomes in infants with biliary atresia (BA). The results showed that CMV infection was associated with worse liver injury, delayed surgery, and increased risk of pretransplant death, but had no effect on native liver survival.

HEPATOLOGY COMMUNICATIONS (2023)

Article Gastroenterology & Hepatology

Thioredoxin reductase 1 regulates hepatic inflammation and macrophage activation during acute cholestatic liver injury

Colin T. Shearn, Aimee L. Anderson, Colin G. Miller, Reed C. Noyd, Michael W. Devereaux, Nata Balasubramaniyan, David J. Orlicky, Edward E. Schmidt, Ronald J. Sokol

Summary: This study investigates the impact of thioredoxin reductase 1 (TrxR1) on liver inflammation and injury during cholestatic liver injury. The results show that TrxR1 expression is increased in inflammatory cells and hepatocytes surrounding fibrosis in cholestatic liver injury patients and mouse models. Inhibition of TrxR1 can alleviate inflammation, necrosis, and the expression of pro-inflammatory cytokines, and increase the expression of antioxidant proteins and bile acid transporters. Therefore, the TrxR1 signaling pathway plays an important role in regulating inflammation and bile acid homeostasis in cholestatic liver injury.

HEPATOLOGY COMMUNICATIONS (2023)

Article Gastroenterology & Hepatology

The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan-aspartate aminotransferase to predict severity of liver disease in children

Alexander Chaidez, Zhaoxing Pan, Shikha S. Sundaram, Julia Boster, Mark Lovell, Ronald J. Sokol, Cara L. Mack

Summary: Vibration controlled transient elastography (Fibroscan) can be used to predict the severity of liver fibrosis and steatosis. This study investigated the correlation between FibroScan measurements and liver histologic features in pediatric nonalcoholic fatty liver disease (NAFLD). The study also assessed the predictive capacity of the FibroScan-aspartate aminotransferase (FAST) score in pediatric NAFLD.

HEPATOLOGY COMMUNICATIONS (2022)

Article Gastroenterology & Hepatology

Impact of long-term administration of maralixibat on children with cholestasis secondary to Alagille syndrome

Benjamin L. Shneider, Catherine A. Spino, Binita M. Kamath, John C. Magee, Rosalinda Ignacio, Suiyuan Huang, Simon P. Horslen, Jean P. Molleston, Alexander G. Miethke, Rohit Kohli, Daniel H. Leung, M. Kyle Jensen, Kathleen M. Loomes, Saul J. Karpen, Cara Mack, Philip Rosenthal, Robert H. Squires, Alastair Baker, Sanjay Rajwal, Deirdre Kelly, Ronald J. Sokol, Richard J. Thompson

Summary: Maralixibat administration is associated with significant improvement in pruritus and quality of life in children with severe cholestasis secondary to Alagille Syndrome.

HEPATOLOGY COMMUNICATIONS (2022)

暂无数据